Biotechnology
Jitters Not Justified
Despite steady selling Thursday the markets are not on the verge of disaster -- and thanks to several IPOs, opportunities are here.
2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land
These two firms have successful drugs and could make nice additions for larger companies.
Novocure Could Climb Even Further; Here's Where to Buy
The oncology company already has risen significantly this year, but its charts indicate the rally could continue.
Pacific Bio Shares Fall on U.K. Antitrust Concern About Illumina Deal
Initial inquiry into deal showed it could remove what might be most significant competitive threat to Illumina.
Biotech, Small Cap Speculation Liven Dull Day in Markets
Takeover action in biotech and speculative interest in small caps kept things interesting during an otherwise sleepy Monday, as everyone awaits Wednesday's Fed decision.
United Natural Foods Is Gathering Ingredients For Opportunity
Appetite is growing for UNFI as the company is cutting debt and surpassing consensus earnings' estimates.
UniQure Jumps on Report It's Exploring a Possible Sale
A report says the biotechnology company is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy.
Savara Shares Slammed on Failed Phase 3 Drug Study
Treatment for rare lung disease misses test goals, sending shares into tailspin.
2 Small Biotechs With Sagging Shares but Promising Prospects
The stocks of these two developmental concerns have slid recently, but there are reasons to believe they will improve.
Spark Therapeutics' Shares Fall on Roche Acquisition Delay
Shares of Spark Therapeutics slide amid a second regulatory-related delay of its $4.3 billion deal with Swiss pharmaceuticals group Roche Holdings AG.